Home > Oncology > ESMO 2020 > Breast Cancer > Prognostic value of tumour infiltrating lymphocytes in young TNBC patients

Prognostic value of tumour infiltrating lymphocytes in young TNBC patients


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Retrospective data of 481 systemically untreated, N0, young TNBC patients showed that increasing stromal tumour infiltrating lymphocytes (TIL) have a prognostic value for improved outcome [1]. The PARADIGM study group selected all women younger than 40 years, diagnosed with Tany/N0/M0 breast cancer between 1989 and 2000, from the Netherlands Cancer Registry, excluding women who received adjuvant systemic treatment. A total of 481 TNBC patients (ER/PR <10% and HER2-negative) were identified (median age 35 years). Most tumours were grade 3 (86%), pT1C (49%). TIL were scored according to an established standard; median TIL score was 25% (IQR 5–70). In these patients, 122 distant recurrence-free survival events (25%; 89 metastases, 33 deaths) and 170 deaths (35%) occurred during a median of 16.2 and 21.2 years follow-up, respectively, and 110 (23%) patients developed a second primary tumour. At 15 years, overall survival (OS) for patients with...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on